Standard BioTools Inc. (LAB)
Standard BioTools Statistics
Share Statistics
Standard BioTools has 378.99M shares outstanding. The number of shares has increased by 28.31% in one year.
| Shares Outstanding | 378.99M |
| Shares Change (YoY) | 28.31% |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | 74.65% |
| Shares Floating | 366.94M |
| Failed to Deliver (FTD) Shares | 6.4K |
| FTD / Avg. Volume | 0.33% |
Short Selling Information
The latest short interest is 13.32M, so 3.58% of the outstanding shares have been sold short.
| Short Interest | 13.32M |
| Short % of Shares Out | 3.58% |
| Short % of Float | 3.7% |
| Short Ratio (days to cover) | 8.1 |
Valuation Ratios
The PE ratio is -4.45 and the forward PE ratio is -10.65. Standard BioTools's PEG ratio is 0.1.
| PE Ratio | -4.45 |
| Forward PE | -10.65 |
| PS Ratio | 3.54 |
| Forward PS | 1.9 |
| PB Ratio | 1.31 |
| P/FCF Ratio | -4.07 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Standard BioTools Inc. has an Enterprise Value (EV) of 221.45M.
| EV / Earnings | -1.59 |
| EV / Sales | 1.27 |
| EV / EBITDA | -1.87 |
| EV / EBIT | -1.26 |
| EV / FCF | -1.46 |
Financial Position
The company has a current ratio of 5.7, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.7 |
| Quick Ratio | 5.09 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.54 |
| Cash Flow / Debt | -4.35 |
| Interest Coverage | -52.85 |
Financial Efficiency
Return on equity (ROE) is -0.29% and return on capital (ROIC) is -34.86%.
| Return on Equity (ROE) | -0.29% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -34.86% |
| Revenue Per Employee | $214,289.93 |
| Profits Per Employee | $-170,620.39 |
| Employee Count | 814 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 2.21 |
Taxes
| Income Tax | 573K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -55.76% in the last 52 weeks. The beta is 1.62, so Standard BioTools's price volatility has been higher than the market average.
| Beta | 1.62 |
| 52-Week Price Change | -55.76% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 1.78 |
| Relative Strength Index (RSI) | 47.57 |
| Average Volume (20 Days) | 1.95M |
Income Statement
In the last 12 months, Standard BioTools had revenue of 174.43M and earned -138.88M in profits. Earnings per share was -0.52.
| Revenue | 174.43M |
| Gross Profit | 84.26M |
| Operating Income | -175.24M |
| Net Income | -138.88M |
| EBITDA | -118.14M |
| EBIT | -175.24M |
| Earnings Per Share (EPS) | -0.52 |
Balance Sheet
The company has 166.73M in cash and 33M in debt, giving a net cash position of 133.73M.
| Cash & Cash Equivalents | 166.73M |
| Total Debt | 33M |
| Net Cash | 133.73M |
| Retained Earnings | -1.19B |
| Total Assets | 612.34M |
| Working Capital | 309.99M |
Cash Flow
In the last 12 months, operating cash flow was -143.45M and capital expenditures -8.36M, giving a free cash flow of -151.81M.
| Operating Cash Flow | -143.45M |
| Capital Expenditures | -8.36M |
| Free Cash Flow | -151.81M |
| FCF Per Share | -0.43 |
Margins
Gross margin is 48.31%, with operating and profit margins of -100.46% and -79.62%.
| Gross Margin | 48.31% |
| Operating Margin | -100.46% |
| Pretax Margin | -79.29% |
| Profit Margin | -79.62% |
| EBITDA Margin | -67.73% |
| EBIT Margin | -100.46% |
| FCF Margin | -87.03% |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -43.7% |
| FCF Yield | -33.66% |
Analyst Forecast
The average price target for LAB is $2.88, which is 142% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.88 |
| Price Target Difference | 142% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 1.99 |
| Piotroski F-Score | 1 |